Stockscreener 앱 받기
4.9004
0.20%
-0.00962
전일 마감가:
$4.91
열려 있는:
$5.01
하루 거래량:
102.61K
Relative Volume:
0.16
시가총액:
$302.63M
수익:
-
순이익/손실:
$-130.41M
주가수익비율:
-2.1877
EPS:
-2.24
순현금흐름:
$-67.76M
1주 성능:
-0.41%
1개월 성능:
+23.12%
6개월 성능:
-36.20%
1년 성능:
+27.94%
1일 변동 폭
$4.835
$5.1079
1주일 범위
$4.74
$5.26
52주 변동 폭
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
GLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.90 | 302.63M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.28 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.63 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.74 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.43 | 35.64B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
265.23 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN
FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus
Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Monte Rosa advances novel inflammatory disease treatment By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 - marketscreener.com
Monte Rosa Therapeutics (GLUE) Gains as FDA Clears New Drug Tria - GuruFocus
Monte Rosa gets FDA clearance to begin testing MRT-8102 (GLUE) - Seeking Alpha
Monte Rosa Therapeutics (GLUE) Gains FDA Approval for MRT-8102 I - GuruFocus
Monte Rosa Therapeutics Announces FDA Clearance Of Ind Application For Mrt-8102 - marketscreener.com
Monte Rosa Therapeutics Announces FDA Clearance of IND - GlobeNewswire
FDA Clearance: Monte Rosa's Revolutionary NEK7 Drug Could Transform Inflammatory Disease Treatment - Stock Titan
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet - sharewise
Two Sigma Advisers LP Takes $180,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Sold by Jane Street Group LLC - Defense World
Squarepoint Ops LLC Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
6,231 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by BNP Paribas Financial Markets - Defense World
ProShare Advisors LLC Buys New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Deutsche Bank AG Buys 6,633 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LP - Defense World
CDK2 degradation inducers disclosed in Monte Rosa patent - BioWorld MedTech
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Monte Rosa CEO Reveals Latest Molecular Glue Degrader Progress at Major Healthcare Conference - Stock Titan
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
D. E. Shaw & Co. Inc. Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World
Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive - simplywall.st
Dimensional Fund Advisors LP Has $1.01 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Increased by Tower Research Capital LLC TRC - Defense World
Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
Monte Rosa Therapeutics Inc (GLUE)’s Day in Review: Closing at 4.22, Up by 9.61 - DWinneX
Monte Rosa Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Raises Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Monte Rosa Therapeutics Reports Strong Q1 2025 Results - MSN
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - MSN
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics (GLUE) Advances Novel Therapeutic Progra - GuruFocus
Monte Rosa Therapeutics, Inc. SEC 10-Q Report - TradingView
Invesco Ltd. Purchases New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
JPMorgan Chase & Co. Acquires 5,551 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Wells Fargo & Company MN Buys 47,952 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.97%
0.52%
자본화:
|
볼륨(24시간):